Ingliforib is primarily investigated for its potential therapeutic applications in the treatment of cancer. It functions as an inhibitor of the enzyme geranylgeranyltransferase I (GGTase-I), which plays a crucial role in the post-translational modification of proteins involved in cell signaling and growth. By inhibiting GGTase-I, Ingliforib disrupts the activation of certain oncogenic proteins, particularly those in the Ras family, which are often implicated in uncontrolled cell proliferation and tumor growth. This mechanism makes it a promising candidate for targeting cancers driven by Ras mutations or other GGTase-I-dependent pathways. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other anticancer therapies.